ESR1 and breast carcinoma: Either way, acting as a ERα antagonist is a therapeutic advantage, since by modulating ERα levels and activation, Oxy hampers the oncogenic properties of this receptor, impairing growth and proliferation of breast cancer cells [3,34,35].